북미 연령 관련 황반변성(AMD) 질환 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력

북미 연령 관련 황반변성(AMD) 질환 시장은 노령 인구 증가, 연령 관련 황반변성(AMD) 질환 유병률 증가, 파이프라인 제품 수요 증가, 연구 개발 투자 증가로 시장 성장과 같은 요인에 의해 주도되고 있습니다. 현재 선진국과 신흥국에서 의료비 지출이 증가하여 제조업체가 새롭고 혁신적인 제품을 개발할 수 있는 경쟁 우위를 확보할 것으로 예상됩니다.

연령 관련 황반변성 유병률은 인구 고령화와 기대 수명 증가로 인해 선진국에서 증가할 것으로 예상됩니다. 환자의 약 60%가 출생 직후에 발생하는 심각한 시각 장애를 앓고 있는 것으로 추정됩니다. 이 질환은 환자의 눈의 중앙 시야가 흐릿해지는 결과를 초래합니다. 연령 관련 황반변성(AMD) 질환 치료 및 진단에 대한 수요는 선진국에서 더욱 증가했습니다. 그러나 치료 및 시술과 관련된 높은 비용과 제품 승인에 대한 엄격한 정부 규정은 연령 관련 황반변성(AMD) 질환 시장의 성장을 방해할 것으로 예상됩니다.

북미 연령 관련 황반변성(AMD) 질환 시장은 긍정적이며 질병의 진행을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 북미 연령 관련 황반변성(AMD) 질환 시장이 2022년에서 2029년까지의 예측 기간 동안 8.0%의 CAGR로 성장할 것이라고 분석합니다.

시장 정의

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

North America Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

• Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the North America incidence of early AMD. -related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the North America age-related macular degeneration (AMD) disease market growth.

• Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the North America age-related macular degeneration (AMD) disease market growth.

Opportunity

•  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country North America. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the North America age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the North America age-related macular degeneration (AMD) disease market.

Restraint/Challenge

• High cost of aesthetic surgical procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the North America age-related macular degeneration (AMD) disease market growth.

Recent Developments

• In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME. This will help the company to commercialize the product in the market in the forecast period.
• In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.

North America age-related macular degeneration (AMD) disease market Segmentation

North America age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

• Dry AMD
• Wet AMD

On the basis of type, the North America age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD..

End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Home Healthcare
• Others

On the basis of end user, the North America age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.

Distribution Channel

• Retail Sales
• Direct Tender

On the basis of distribution channel, the North America age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.

Age-Related Macular Degeneration (AMD) Disease Market Regional Analysis/Insights

The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.

The countries covered in the age-related macular degeneration (AMD) disease report are U.S., Canada and Mexico.

The U.S. is expected to dominate due to increasing technological advancement in the developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Age-Related Macular Degeneration (AMD) Disease Market Share Analysis

북미 연령 관련 황반변성(AMD) 질환 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 북미 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 연령 관련 황반변성(AMD) 질환 시장에 대한 회사의 초점과만 관련이 있습니다.

시장의 주요 기업으로는 Novartis AG, Bayer AG, Astellas Pharma Inc., REGENXBIO Inc., Ionis Pharmaceutics, Ocugen Inc, Johnson & Johnson Services, Inc., IVERIC bio, MeiraGTx Limited, Adverum Biotechnologies, Inc., Graybug Vision Inc., Kodiak Sciences Inc., Genentech Inc. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 북미 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.

SKU-68460